Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 7/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | AMD1 | P17707 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL325253 | 1.00 | RXFP1 (0.42) | RXFP1ADKPI4KAPI4K2BPI4K2A | |
| SCHEMBL18009841 | 0.90 | RXFP1 (0.43) | RXFP1ADKPI4KAPI4K2BPI4K2A | |
| SCHEMBL18572818 | 0.90 | ADK (0.45) | RXFP1ADKPI4KAPI4K2BPI4K2A | |
| SCHEMBL59535 | 0.89 | ADK (0.53) | RXFP1ADKPI4KAPI4K2BPI4K2A | |
| SCHEMBL20418987 | 0.89 | ADK (0.53) | RXFP1ADKPI4KAPI4K2BPI4K2A | |
| SCHEMBL4165064 | 0.89 | ADK (0.53) | RXFP1ADKPI4KAPI4K2BPI4K2A | |
| SCHEMBL18026249 | 0.85 | PI4KA (0.44) | RXFP1ADKPI4KAPI4K2BPI4K2A | |
| SCHEMBL18535300 | 0.84 | PI4KA (0.55) | RXFP1ADKPI4KAPI4K2BPI4K2A | |
| SCHEMBL18009754 | 0.84 | PI4KA (0.55) | RXFP1ADKPI4KAPI4K2BPI4K2A | |
| SCHEMBL1795283 | 0.82 | RXFP1 (0.54) | RXFP1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093226-B2 | Cytostatic 7-deazapurine nucleosides | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2012-01-10 | — | — | US | disclosed |
| US-20090203637-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203637-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | TYMP, TYMS, DPYD | RXFP1 4742/4885ADK 442/4885PI4KA 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.